Author

L. Grzelak

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 4 Microbiology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 6 Research Focus:host-pathogen & immune response· 5 Approach:experimental assay· 4 Assay:proteomics· 4 Research Focus:differential expression· 2 Research Focus:gene regulatory network inference· 2 Research Focus:benchmarking· 1 Assay:bulk RNA-seq· 1

Frequent Co-Authors

H. Mouquet· 6 shared O. Schwartz· 6 shared C. Planchais· 5 shared D. Planas· 4 shared F. Guivel-Benhassine· 4 shared F. Porrot· 4 shared T. Bruel· 4 shared E. Simon-Loriere· 3 shared

Activity by Year

2021-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

6 shared papersImmunology

H. Mouquet

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies

D. Planas, T. Bruel, I. Staropoli, F. Guivel-Benhassine, F. Porrot, P. Maes, L. Grzelak, M. Prot, S. Mougari, C. Planchais, J. Puech, M. Saliba, R. Sahraoui, F. Femy, N. Morel, , O. Schwartz

This study evaluates the neutralizing antibody resistance of SARS-CoV-2 Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to monoclonal antibodies and sera from vaccinated individuals.

bioRxiv · Nov 17, 2022Microbiology

IRF8 regulates efficacy of therapeutic anti-CD20 monoclonal antibodies

L. Grzelak, F. Roesch, A. Vaysse, A. Biton, F. Porrot, P.-H. Commere, C. Planchais, H. Mouquet, M. Vignuzzi, T. Bruel, O. Schwartz

This study identifies IRF8 as a regulator of CD20 expression and anti-CD20 antibody efficacy through CRISPR screening and functional validation in B cells.

bioRxiv · Jun 9, 2022Immunology

Potent Human Broadly SARS-CoV-2 Neutralizing IgA and IgG Antibodies Effective Against Omicron BA.1 and BA.2

C. Planchais, I. Fernandez, T. Bruel, G. Dias de Melo, M. Prot, M. Beretta, P. Guardado-Calvo, J. Dufloo, L. M. Molinos-Albert, M. Backovic, J. Chiaravalli, E. Giraud, B. Vesin, L. Conquet, L. Grzelak, , H. Mouquet

The paper identifies potent broadly neutralizing IgA and IgG antibodies against SARS-CoV-2 variants, including Omicron BA.1 and BA.2, from memory B cells in convalescents.

bioRxiv · Apr 1, 2022Immunology

SARS-CoV-2 Alpha, Beta and Delta variants display enhanced Spike-mediated Syncytia Formation

M. M. Rajah, M. Hubert, E. Bishop, N. Saunders, R. Robinot, L. Grzelak, D. Planas, J. Dufloo, S. Gellenoncourt, A. Bongers, M. Zivaljic, C. Planchais, F. Guivel-Benhassine, F. Porrot, H. Mouquet, , O. Schwartz

This study compares syncytia formation by SARS-CoV-2 Alpha, Beta, and Delta variants to D614G, finding enhanced fusogenicity and differential effects of mutations on ACE2 binding and antibody escape.

bioRxiv · Jun 11, 2021Microbiology

A monocyte/dendritic cell molecular signature of SARS-CoV2-related multisystem inflammatory syndrome in children (MIS-C) with severe myocarditis

C. de Cevins, M. Luka, N. Smith, S. Meynier, A. Magerus, F. Carbone, V. Garcia Paredes, L. Barnabei, M. Batignes, A. Boulle, M.-C. Stolzenberg, B. P. Perot, B. Charbit, T. Fali, V. Pirabarakan, , Gras Leguen

The paper identifies a monocyte/dendritic cell gene signature in severe MIS-C with myocarditis, linked to NF-κB activity and cytokine signaling.

bioRxiv · Feb 23, 2021Immunology

Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

D. Planas, T. Bruel, L. Grzelak, F. Guivel-Benhassine, I. Staropoli, F. Porrot, C. Planchais, J. Buchrieser, M. M. Rajah, E. Bishop, M. Albert, F. Donati, S. Behillil, V. Enouf, M. Marianne, , O. Schwartz

This study assesses the neutralization sensitivity of SARS-CoV-2 B.1.1.7 and B.1.351 variants compared to D614G using sera and nasal swabs, finding reduced efficacy against B.1.351 in some convalescent and vaccinated individuals.

bioRxiv · Feb 12, 2021 · PreprintImmunology